東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Explaining innovation in the United ...

Ratcliffe, Aran E.

Linked to FindBook

Google Book

Amazon

博客來

Explaining innovation in the United States pharmaceutical industry.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Explaining innovation in the United States pharmaceutical industry./
Author:	Ratcliffe, Aran E.
Description:	187 p.
Notes:	Chair: William S. Comanor.
Contained By:	Dissertation Abstracts International61-11A.
Subject:	Economics, Commerce-Business. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=9995851
ISBN:	0493034633

Explaining innovation in the United States pharmaceutical industry.
Ratcliffe, Aran E.

Explaining innovation in the United States pharmaceutical industry. - 187 p.

Chair: William S. Comanor.

Thesis (Ph.D.)--University of California, Santa Barbara, 2000.

I introduce an R&D knowledge production function and model counts of FDA approvals of an NME as a function of lagged R&D expenditures, public and private R&D knowledge, and the breadth of R&D operations.

ISBN: 0493034633Subjects--Topical Terms:

626649
Economics, Commerce-Business.

Explaining innovation in the United States pharmaceutical industry.
LDR:03272nam 2200337 a 45 001 938632
005 20110512
008 110512s2000 eng d
020 $a 0493034633
035 $a (UnM)AAI9995851
035 $a AAI9995851
040 $a UnM $c UnM
100 1 $a Ratcliffe, Aran E. $3 1262607
245 1 0 $a Explaining innovation in the United States pharmaceutical industry.
300 $a 187 p.
500 $a Chair: William S. Comanor.
500 $a Source: Dissertation Abstracts International, Volume: 61-11, Section: A, page: 4485.
502 $a Thesis (Ph.D.)--University of California, Santa Barbara, 2000.
520 $a I introduce an R&D knowledge production function and model counts of FDA approvals of an NME as a function of lagged R&D expenditures, public and private R&D knowledge, and the breadth of R&D operations.
520 $a This research is an examination of the determinants of the productivity of research and development (R&D) in the US pharmaceutical industry. The pharmaceutical industry is the most R&D-intensive of all US industries and has seen intense horizontal merger activity in recent years. The pharmaceutical industry is thus a prime candidate for the analysis of the determinants of its productivity.
520 $a Specifically, this study tests for technological/knowledge spillovers, returns to diversification versus specialization of the R&D portfolio, and economies of scale in R&D. This research is the first to use confidential US Census Bureau data on both private and public pharmaceutical firms in addressing these issues. The estimation of the optimal degree of diversification of pharmaceutical R&D is also unique to this study, while only one other study has considered R&D spillovers in the pharmaceutical industry.
520 $a The empirical results show that there are significant and meaningful R&D spillovers both between firms and within firms, suggesting that an optimal R&D strategy may be to either merge with other firms with similar R&D portfolios, or to wait for rivals to innovate and then mimic or ‘piggy back’ rivals' research.
520 $a I also find evidence to support the notion of an optimal degree of diversification of a pharmaceutical firm's R&D portfolio. This evidence is consistent with observed behavioral trends in the industry: firms do not typically specialize and focus their research activities in one particular therapeutic category, nor do they get involved in <italic>every</italic> research area.
520 $a Finally, the empirical results show that the marginal physical product of R&D initially rises with firm size and then falls as diminishing returns set in for the largest firms. Such evidence might be cited as a driving force behind recent mergers in the industry. Cost-cutting and other productive synergies are, in fact, the very explanations that the merging firms use to promote the mergers that we observe in this industry.
590 $a School code: 0035.
650 4 $a Economics, Commerce-Business. $3 626649
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0505
690 $a 0572
710 2 0 $a University of California, Santa Barbara. $3 1017586
773 0 $t Dissertation Abstracts International $g 61-11A.
790 $a 0035
790 1 0 $a Comanor, William S., $e advisor
791 $a Ph.D.
792 $a 2000
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=9995851